View in EDS HTML Full Text PDF Full Text

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.

Saved in:
Bibliographic Details
Title: A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
Authors: Fisher TS; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA. timothy.s.fisher@pfizer.com.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA. timothy.s.fisher@pfizer.com.; Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA. timothy.s.fisher@pfizer.com., Hooper AT; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Lucas J; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Clark TH; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., Rohner AK; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Peano B; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Elliott MW; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Tsaparikos K; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Wang H; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Golas J; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Gavriil M; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA., Haddish-Berhane N; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.; Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA, USA., Tchistiakova L; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., Gerber HP; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA., Root AR; BioMedicine Design Pfizer Inc., Cambridge, MA, USA., May C; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA.
Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2018 Feb; Vol. 67 (2), pp. 247-259. Date of Electronic Publication: 2017 Oct 24.
Publication Type: Journal Article
Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29067496
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fisher+TS%22">Fisher TS</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA. timothy.s.fisher@pfizer.com.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA. timothy.s.fisher@pfizer.com.; Pfizer Inc., 10777 Science Center Drive, San Diego, CA, 92121, USA. timothy.s.fisher@pfizer.com.<br /><searchLink fieldCode="AU" term="%22Hooper+AT%22">Hooper AT</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Lucas+J%22">Lucas J</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Clark+TH%22">Clark TH</searchLink>; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Rohner+AK%22">Rohner AK</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Peano+B%22">Peano B</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Elliott+MW%22">Elliott MW</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Tsaparikos+K%22">Tsaparikos K</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Wang+H%22">Wang H</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Golas+J%22">Golas J</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Gavriil+M%22">Gavriil M</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Haddish-Berhane+N%22">Haddish-Berhane N</searchLink>; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.; Johnson and Johnson Pharmaceutical Research and Development, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Tchistiakova+L%22">Tchistiakova L</searchLink>; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Gerber+HP%22">Gerber HP</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA.<br /><searchLink fieldCode="AU" term="%22Root+AR%22">Root AR</searchLink>; BioMedicine Design Pfizer Inc., Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22May+C%22">May C</searchLink>; Oncology Research and Development Pfizer Inc., La Jolla, CA, USA.; Oncology Research and Development Pfizer Inc., Pearl River, NY, USA.; Maverick Therapeutics, Brisbane, CA, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228605732%22">Cancer immunology, immunotherapy : CII</searchLink> [Cancer Immunol Immunother] 2018 Feb; Vol. 67 (2), pp. 247-259. <i>Date of Electronic Publication: </i>2017 Oct 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Verlag%22">Springer Verlag </searchLink><i>Country of Publication: </i>Germany <i>NLM ID: </i>8605732 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1432-0851 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203407004%22">03407004 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Immunol Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29067496
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s00262-017-2081-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 247
    Titles:
      – TitleFull: A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fisher TS
      – PersonEntity:
          Name:
            NameFull: Hooper AT
      – PersonEntity:
          Name:
            NameFull: Lucas J
      – PersonEntity:
          Name:
            NameFull: Clark TH
      – PersonEntity:
          Name:
            NameFull: Rohner AK
      – PersonEntity:
          Name:
            NameFull: Peano B
      – PersonEntity:
          Name:
            NameFull: Elliott MW
      – PersonEntity:
          Name:
            NameFull: Tsaparikos K
      – PersonEntity:
          Name:
            NameFull: Wang H
      – PersonEntity:
          Name:
            NameFull: Golas J
      – PersonEntity:
          Name:
            NameFull: Gavriil M
      – PersonEntity:
          Name:
            NameFull: Haddish-Berhane N
      – PersonEntity:
          Name:
            NameFull: Tchistiakova L
      – PersonEntity:
          Name:
            NameFull: Gerber HP
      – PersonEntity:
          Name:
            NameFull: Root AR
      – PersonEntity:
          Name:
            NameFull: May C
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Text: 2018 Feb
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1432-0851
          Numbering:
            – Type: volume
              Value: 67
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Cancer immunology, immunotherapy : CII
              Type: main
ResultId 1